London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Porky9 Social media has becomed the drug of choice for billions of people . No wonder the world has lost it's sense of priority. Lips fillers ,and botox injections now take precedence over cancer treatment.
@Andysel It's so annoying as really in the bigger picture its not actually that much cash to fully fund a P3. Just more than they have currently hence the need for a partner to help fund this stage. 20m USD that's about 16m Sterling.
'Let's wave a magic wand and assume they acquire or kit out own lab
Does anyone know if they have the skill sets to continue working on 201 without TRX to go it alone and position it themselves for the next phase of trials?
Apart from cash do the Americans bring much else to the party? Anyone know?'
I was asking about the Americans (THx) in my debut post but was told suzy had informed all that thx had gone stealth as that supposedly benefits negotiations? Not much if any info on the Americans online..when thx formed? Or showreel for the two main guys showcasing experience of doing similar fundraising in past etc..Suzy and team of course must have done all checks on them obviously.
Talk on here about Suzy doing more but was thinking what more can she do in regards of the deal. Surely it all lies with thx and those looking to invest...thx have to sell it as a good opportunity And maybe world events and related economic issues are effecting minds potential investors
Hoosierdaddy- curious where u got 7 wks past the long stop date? Last rns stated 'As announced on 2 November 2021, ValiRx entered into a non-binding Letter of Intent ("LOI") with TheoremRx for the sub-license of VAL201. The LOI has been re-executed with an exclusivity period expiring before the end of June 2022.'
From this (maybe naively) I have in my own mind that the long stop date is end of June? Or have I missed something?
There's still approximately another 6 wks till the last day of June. . . . .
@Andysel The lab is a massive value add to the long term plans, makes sense and will get covered imo. I am very confident of that. No wand required.
Let me rephrase my second question; on the assumption then that you think they have the skills to develop 201 in the trials themselves. How much cash approximate would it take to fund inhouse the trial stages? Could shareholders support that cost to get it over the line?? What are we talking??
As far as I'm concerned 201 is potentially an amazing asset , when that drug is positioned the Value will be significant. I'm thinking can it all be done in the UK without creating a stateside SPV and US involvement?
Interested if anyone has ideas on this, if not i will try and research how other Bios have done it and the costs involved....
Let's wave a magic wand and assume they acquire or kit out own lab - we don't have a magic wand
Does anyone know if they have the skill sets to continue working on 201 without TRX to go it alone and position it themselves for the next phase of trials? - VAL do have the skill set as they have/are being instrumental in assessing the vendors for the trials, the issue is funding the clinical trials.
The Lab would not be to enable VAL to carry out their assessments on future opportunities in house rather than outsourcing as they currently do, and in addition charge others for their services creating a revenue stream.
Apart from cash do the Americans bring much else to the party? Anyone know? - for this we will have to wait and see what else they bring to the table when the sub license has been completed.
And here we are, the 19th of May 7 WEEKS past her absolute long stop date and not a sausage. But, at least they are constantly updating us how much they appreciate all these other companies doing their own work.... Here's an idea for you Suzy, Instead of appreciating all their hard work, no doubt benefitting their own share holders, get on the phone to TRX, The mysterious Japanese company, and let your shareholders be the one's tweeting how appreciative we are of our CEO for getting 201 deal done. Sayonara
TRX have been very smart. They have let the timelines slip because it helps there negotiating position
The longer this goes right, the more the market wobbles and shareholders get jittery. Also the cash burn continues and any cash raise gets closer if no deal is done. Then the dilution becomes more likely and the spiral continues.
TRX then offer to save the day on a cut price commercial deal, because they hold the cards on the exclusivity.
I’ve said this from the start Val are commercially naive, not being harsh, this is my own view
Others may think differently but I will only change my view once I see real evidence of something to the contrary
I’m buyer and a long term holder before everyone starts to jump down my throat!
The company will likely need funding if 201 deal fails with TRX,don’t forget we aren’t a 1 trick pony,201 as much as it’s important for investor confidence is well down the list of company transforming products that Valirx are dealing with.
If Val is top of the List why dont TheoremRx raise specifically for it and deal with the balance financing separately if indeed it is the balance or part(s) within that are the reasons for the delays thus far.
Personally, if the current extension is missed; I think Val should move on.